The safety of clozapine in the elderly

Expert Opinion on Drug Safety

Volumn 7, Issue 5, 2008, Pages 525-538

  Gareri, Pietro ^a,b   De Fazio, Pasquale ^a   Russo, Emilio ^a   Marigliano, Norma ^a   De Fazio, Salvatore ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b ASP Catanzaro   (Italy)

Author keywords

Adverse effects; Agranulocytosis; Cytochromes; Dozapine; Elderly; Genetic polymorphism; Safety

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOTOXIC AGENT; DIAZEPAM; ERYTHROMYCIN; FLUVOXAMINE; HALOPERIDOL; LIDOCAINE; NORCLOZAPINE; OLANZAPINE; OMEPRAZOLE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TACRINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; NEUROLEPTIC AGENT;

ACCOMMODATION PARALYSIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; AROUSAL; BEDTIME DOSAGE; BLURRED VISION; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG CONTROL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ELDERLY CARE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GERIATRIC ASSESSMENT; GRAND MAL SEIZURE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTHERMIA; INFECTION; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; MEDLINE; METABOLIC DISORDER; MYOCARDITIS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PERICARDITIS; POLYSEROSITIS; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SELENIUM DEFICIENCY; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; URINE RETENTION; VOMITING; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; XEROSTOMIA; AGED; CHEMICALLY INDUCED DISORDER; MENTAL DISEASE; METHODOLOGY; PARKINSON DISEASE;

AGED; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; GERIATRIC ASSESSMENT; HUMANS; MENTAL DISORDERS; MYOCARDITIS; PARKINSON DISEASE;

EID: 54449085678     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.5.525     Document Type: Review

References (96)

1. Gareri P, De Fazio P, De Fazio S, et al. Adverse effects of atypical antipsychotics in the elderly. Drugs Aging 206;23(12):937-56
2. FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioural disturbances. 11 Apri1 2005. Available from: http://www.fda.gov
3. Gareri P, De Fazio P, Stilo M, et al. Conventional and atypical antipsychotics in the elderly. Clin Drug Invest 2003;23:287-322
4. EMEA. Committee for proprietary medicinal products (CPMP) summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001/83/EC for Leponex and associated
5. WHO Pharmaceuticals Newsletter. Regulatory matters - clozapine, blood monitoring requirements tightened. 2006, no. 1, page 1. Available from: http://www.who.int/medicinedocs
6. Indanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol 1977;11:193-8
7. Clozapine. Retrieved from: htpp://en.wikipedia.org/wiki/Clozapine
8. Naheed M, Green B. Focus on clozapine. Curr Med Res Opin 2001;17:223-9
9. Meltzer HY. Treatment resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997;14:1-20
10. Volavka J, Zito JM, Vitrai J, Czobar P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-9
11. Spivak B, Mester R, Wittenberg N, et al. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic treatment resistant schizophrenic patients. Clin Neuropharmacol 1997;20:442-6
12. Barak Y, Wittenberg N, Naor S, et al. Clozapine in elderly psychiatric patients: tolerability, safety and efficacy. Compr Psychiatry 1999;40:320-5
13. Novartis Pharmaceuticals. Prescribing Information, April 1006. p 36. Avaiiable from: http://www.novartis.ca/downloads/en/products/ clozafil_scrip_e.pdf Retrieved on 2007-06-29
14. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997;171:109-12
15. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics: part I pharmacology, pharmacokinetics and efficacy. Ann Pharmacother 1999;33:73-85
16. Leysen JE, Janssen PMF, Heylen L, et al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects.Int J Psychiatr Clin Pract 1998;2:S3-17
17. De Leon J, Odom-White A, Josiassen R, et al. Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol 2003;23:336-41
18. Gareri P, Falconi U, De Fazio P, De Sarro G. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol 2000;61:353-96
19. Galeotta G, Paoletti V, Mammarella A, et al. La terapia farmacologica nel paziente anziano. Clin Ter 1990;135:181-92
20. Greenblatt DJ, Selers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982;306:1081-8
21. Schaber G, Stevens I, Gaertner HJ, et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol 1998;46:453-9
22. Gareri P, Stilo G, Bevacqua I, et al. Antidepressant drugs in the elderly. Gen Pharmacol 1998;30:465-75
23. Montamat SC, Cusack BJ, Yestal RE. Management of drug therapy in the elderly. N Engl J Med 1989;321:303-9
24. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985;29:342-75
25. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82:87-96
26. Marzolini C, Paus E, Buclin T, et al. Polymorphism in human MDR1 (P-glycoprotein). Recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
27. Lane HY, Jann MW, Chang YC, et al. Repeated ingestion of grapefruit juice does not alter clozapine's steady state plasma levels. J Clin Psychiatry 2001;62:812-7
28. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46
29. Flanagan RJ, Yusufi B, Barnes TRE. Comparability of whole-blood and plasma clozapine and norclozapine concentrations. Br J Clin Pharmacol 2003;56:135-8
30. Hermida J, Paz E, Tutor JC. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit 2008;30:41-5
31. CSLS Handbook Search Results. Clozapine and norclozapine: serum/plasma. 2005. Available from: www.cs.nsm.gov.au/csls
32. Bertilsson L, Dahl ML, Sjoqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993;341:63
33. Gonzalez FJ, Skoda RC, Kinenza S. Characterization of the common genetic defect in human deficient in debrisoquine metabolism. Nature 1988;331:442-6
34. Gonzalez FJ, Korzekwa KR. Cytochromes P450 expression sites. Ann Rev Pharmacol Toxicol 1995;35:369-90
35. Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18:393-6
36. Derenne JL, Baldessarini RJ. Cloapine toxicity associated with smoking cessation: case report. Am J Ther 2005;12:469-71
37. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007;64:1917-21
38. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997;171:109-12
39. Frick A, Kopitz J, Bergemann N. Omeprazole reduces clozapine concentrations. Pharmacopsychiatry 2003;36:121-3
40. Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they?. Curr Drug Metab 2007;8:307-13
41. Kalow W, Tang B. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase ratios. Clin Pharmacol Ther 1991;50:508-19
42. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004;76:618-27
43. O'Connell M, Frye RF, Matzke GR, et al. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol 2006;46:1299-307
44. Doude van Troostwijk LJAE, Koopmans RP, Vermeulen HDB, et al. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 2003;20:451-7
45. Allorge D, Chevalier D, Lo-Guidice JM, et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 2003;56:341-4
46. Callaghan J, Bergstrom R, Ptak L, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37;177-93
47. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999;60;36-40
48. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16:S37-50
49. Brunello N. Interazioni farmacocinetiche degli antidepressivi. In: Vella G, Siracusano A, editors. La depressione nell'anziano. Il Pensiero Scientifico Editore: NOOS, Rome; 1998;4:16-28
50. Michielsen PJ, Thunnissen MM, Van Den Bossche B. Clozapine and selective reuptake inhibitors: risks of toxicity. Tijdschr Psychiatr 2007;49:655-9
51. Parkinson A, Mudra D, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199;193-209
52. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-88
53. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5
54. Labbè L, Sirois C, Pilote S, et al. Effect of gender, sex hormones, time variables, and physiologic urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000;10:425-38
55. Ohara K, Tanabu S, Ishibashi K, et al. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:347-50
56. Bachmann K, Belloto RJ. Differential kinetics of phenytoin in elderly patients. Drugs Aging 1999;15;235-50
57. Safar M. Ageing and its effects on the cardiovascular system. Drugs 1990;39:1-8
58. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-7
59. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 2003;329:162-7
60. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Physchiat 1999;175:576-80
61. Kleinen JM, Bouckaert F, Peuskens J. Clozapine-induced agranulocytosis and Sweet's syndrome in a 74-year-old female patient. A case study. Tijdschr Psychiatr 2008;50:119-23
62. Kutscher RC, Robbins GP, Kennedy WK, et al. Clozapine-induced leucopenia successfully treated with lithium. Am J Health Syst Pharm 2007;64:2027-31
63. Clinical data launches pharmacogenetic test for clozapine-induced agranulocytosis on schedule. PGxPredict: CLOZAPINE™, 2007. Available from: www.clda.com
64. Jeste DV, Eastham JH, Lohr JB. Treatment of behavioural disorders and psychosis. In: Salzman C, editor. Clinical geriatric psychopharmacology, Baltimore (MD): Williams & Wilkins; 1998;6:106-49
65. SoRelle R. Predicting stroke after myocardial infarction in the elderly. Circulation 2002;105:E9079-80
66. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57
67. Low RA Jr, Fuller MA, Popli A. Clozapine-induced atrial fibrillation [letter]. J Clin Psychopharmacol 1998;18:170
68. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-72
69. Ghaeli P, Dufresen RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-81
70. Wirshing WC. The new antipsychotic compounds: is a clinical choice algorithm possible? West J Med 1998;169:43-4
71. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
72. Kuoppomaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonist. Eur J Pharmacol 1993;245:179-82
73. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004;24:70-8
74. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83
75. Mir S, Taylor D. Atypical antipsychotics and hyperglicaemia. Int Clin Psychopharmacol 2001;16:63-74
76. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-11
77. Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis. Aust N Z J Psychiatry 1999;33:120-1
78. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
79. Vaddadi KS, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol 2003;55:307-9
80. Torta R. Prontuario dei farmaci per il Sistema Nervoso Centrale. Turin: Solvay Pharma SPA; 2000
81. Hung TH, Lee Y, Chang YY, et al. Reversible Pisa syndrome induced by clozapine: a case report. Clin Neuropharmacol 2007;30:370-2
82. Young RM, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004;185:147-51
83. Lim A, Sivakumaran P, Israel M. Clozapine-associated polyserositis. N Z Med J 2003;116:U651
84. Estebanez C, Fernandez Reyes MJ, Sanchez Hernandez R, et al. Acute interstitial nephritis caused by clozapine. Nefrologia 2002;22:277-81
85. Landry P, Benaliouad F, Tessier S. Increased use of antibiotics in clozapine-treated patients. Int Clin Psychopharmacol 2003;18:297-8
86. Sachdev P, Kruk J, Keebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1997;17:233-4
87. Tsai G, Crisostomo G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995;7:91-5
88. Meltzer HY. Treatment resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997;14:1-20
89. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70
90. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395
91. Yusufi B, Mukherjee S, Flanagan R, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007;22:238-43
92. Lee HB, Hanner JA, Yokley JL, et al. Clozapine for treatment-resistant agitation in dementia. J Geriatr Psychiatry Neurol 2007;20;178-82
93. Meyniel C, Damier P. Lewy body dementia and Parkinson disease dementia. Presse Med 2007;36:1485-90
94. Gareri P, Cotroneo A, Lacava R, et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia. Arch Gerontol Geriatr 2004;(Suppl 9):207-15
95. Gareri P, Cotroneo A, Marchisio U, et al. Risperidone in the treatment of behavioral disorders in elderly patients with dementia. Arch Gerontol Geriatr 2001;(Suppl 7):173-82
96. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotic to risperidone be beneficial for elderly schizophrenic patients?: a naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002;22:115-20